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ATRX (alpha thalassemia/mental retardation syndrome X-linked) belongs to the SWI2/SNF2 family of chromatin
remodeling proteins. Besides the ATPase/helicase domain at its C terminus, it contains a PHD-like zinc finger at the N
terminus. Mutations in the ATRX gene are associated with X-linked mental retardation (XLMR) often accompanied by alpha
thalassemia (ATRX syndrome).AlthoughATRXhas been postulated to be a transcriptional regulator, its precise roles remain
undefined. We demonstrate ATRX localization at the telomeres in interphase mouse embryonic stem (ES) cells in synchrony
with the incorporation of H3.3 during telomere replication at S phase. Moreover, we found that chromobox homolog 5
(CBX5) (also known as heterochromatin protein 1 alpha, or HP1 alpha) is also present at the telomeres in ES cells. We show by
coimmunoprecipitation that this localization is dependent on the association of ATRX with histone H3.3, and that mutating
the K4 residue of H3.3 significantly diminishes ATRX and H3.3 interaction. RNAi-knockdown of ATRX induces a telomere-
dysfunction phenotype and significantly reduces CBX5 enrichment at the telomeres. These findings suggest a novel function
of ATRX, working in conjunction with H3.3 and CBX5, as a key regulator of ES-cell telomere chromatin.
[Supplemental material is available online at http://www.genome.org.]
The ATRX (alpha thalassemia/mental retardation syndrome
X-linked) gene (Picketts et al. 1996) is located on the X chromo-
some (Xq13). It is a large gene spanning ;300 kb and contains
36 exons. It encodes at least two alternatively spliced, 10.5-kb
mRNA transcripts that differ at their 59 ends and are predicted to
give rise to slightly different proteins of 280 and 265 kDa. It is a
member of the SNF2 family of helicase/ATPases that contribute to
the remodeling of nucleosome structure (Argentaro et al. 2007). In
the C-terminal half of the protein is the helicase/adenosine tri-
phosphatase (ATPase) domain comprising seven highly conserved
helicase/ATPase motifs. At the N terminus is the ATRX-DNMT3-
DNMT3L (ADD) domain (Argentaro et al. 2007) that is a plant
homeodomain (PHD)–like zinc finger with an additional C2-C2
motif. Other proteins that share this motif are DNMT3A,
DNMT3B, and DNMT3L, three proteins involved in DNA meth-
ylation. PHD fingers are common features of chromatin-related
proteins (Nagamine et al. 1997; Lu et al. 1998; Bienz 2006) and
function to help tether proteins to chromatin and have a prefer-
ence for binding the methylated lysine residue of H3. There is also
evidence that the ADD domain of ATRX plays a role in DNA
binding (Cardoso et al. 2000). In human and mouse cells, ATRX is
highly enriched at pericentric heterochromatin and is associated
with chromobox homolog 5 (CBX5) (also known as HP1 alpha
[heterochromatin protein 1 alpha]), DAXX, MECP2, and promye-
locytic leukemia (PML) nuclear bodies (McDowell et al. 1999; Xue
et al. 2003; Ishov et al. 2004; Kourmouli et al. 2005; Nan et al. 2007).
The association of ATRXmutations with a reduction in alpha
globin synthesis in alpha thalassemia patients suggests that the
protein plays a role in the regulation of alpha globin gene expres-
sion. However, the pleiotropic ATRX syndrome comprising mul-
tiple congenital abnormalities, including profounddevelopmental
delay, facial dysmorphism, and genital abnormalities, suggests that
ATRX is involved in the regulation of other yet unidentified genes.
The complex function of ATRX in the developmental process is
also apparent in ATRX-null mice. ATRX-null male mice are not
viable, and embryos die around 9.5 days post-coitum (dpc) (Berube
et al. 2002, 2005; Garrick et al. 2006). Also, conditional ablation of
full-length ATRX in the mouse forebrain results in decreased cor-
tical size (Guerrini et al. 2000), consistent with mental retardation
in patients carrying ATRXmutations. It is also interesting that loss
of ATRX in ES cells leads to reduced cell-growth and a higher rate of
spontaneous differentiation (Garrick et al. 2006), suggesting that
ATRX plays a role in controlling embryonic stem (ES) cell pro-
liferation and differentiation, in addition to its function for sister
chromatid cohesion and chromosome congression during mitosis
(Ritchie et al. 2008).
Inmammalian cells, telomeric chromatin contains epigenetic
markers characteristic of silenced chromatin such as those found at
pericentric heterochromatin (Garcia-Cao et al. 2004; Gonzalo et al.
2005, 2006). Knockout deletion of the histone and DNA methyl-
transferases (SUV39H1/2, SUV420H1/2, DNMT3A/B, andDNMT1)
in the mouse results in defective telomere function, aberrantly in-
creased telomere length, and chromosomal instability, suggesting
5Corresponding author.
E-mail lee.wong@mcri.edu.au; fax 61-3-93481391.
Article published online before print. Article and publication date are at http://
www.genome.org/cgi/doi/10.1101/gr.101477.109.
20:351–360  2010 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/10; www.genome.org Genome Research 351
www.genome.org
 Cold Spring Harbor Laboratory Press on February 1, 2016 - Published by genome.cshlp.orgDownloaded from 
that these repressive markers are essen-
tial for telomere length maintenance and
structural integrity.
H3.3 is a universal histone predom-
inantly incorporated into transcription
sites and associated with active and
open chromatin (Loyola et al. 2006). H3.3
phosphorylated at serine 31 (H3.3S31P) is
a mitosis-specific marker enriched in the
pericentric heterochromatin (Hake et al.
2005). Recently, we have shown the en-
richment of H3.3S31P at metaphase
telomeres in mouse ES cells and embry-
onic germ (EG) cells, but not in non-
pluripotent cells or differentiated ES cells
(Wong et al. 2009). In addition, we have
shown localization of H3.3 at interphase
telomeres in mouse ES cells. In ES cells
undergoing differentiation, H3.3 level
at the telomeres decreases, accompanied
by increased association of heterochro-
matin repressive markers H4K20me3 and
H3K9me3. Our findings in ES cells chal-
lenge the long-standing notion that the
telomere chromatin is ‘‘silenced,’’ and
are the first to show the existence of a
unique and functionally essential telo-
mere chromatin in ES cells that under-
goes dynamic differentiation-dependent
remodeling.
In this study, we demonstrate that ATRX localizes tomouse ES
cell telomeres during interphase. The association of ATRXwith the
telomeres is synchronized with the incorporation of H3.3 at the
telomeres during telomere-replication at S phase.We show a direct
interaction between ATRX and H3.3 by chromatin immunopre-
cipitation analysis and site-directed mutagenesis of H3.3. RNAi-
mediated inhibition of ATRX in mouse ES cells induces an in-
creased telomere-dysfunction phenotype and a decrease in CBX5
binding at the telomeres. We propose that ATRX, through in-
teraction with H3.3 and CBX5, plays a novel function as a key
regulator of telomere chromatin in ES cells.
Results
ATRX localizes at telomeres in interphase
mouse ES and EG cells
Previous studies have shown that ATRX localizes at pericentric
heterochromatin and PML nuclear bodies through interaction
with the chromoshadow domain (CSD) of CBX5 andMECP2 and
recruitment byDAXX (McDowell et al. 1999; Xue et al. 2003; Ishov
et al. 2004; Kourmouli et al. 2005; Nan et al. 2007). Here, we show
that ATRX, in addition to its localization at the pericentric het-
erochromatin (Supplemental Fig. S1A,B), is prominently present at
the telomeres in pluripotent mouse ES cell lines ES129.1 (Fig. 1A)
and ES-W9.5 (Fig. 1B) during interphase. Specificity of the antise-
rum was confirmed by competitive immunofluorescence analysis
with ATRX peptide (Supplemental Fig. S2A–D). Telomeric local-
ization of ATRX was confirmed by FISH analysis using a telo-
mere-specific TTAGGG probe. As ATRX associates with pericentric
heterochromatin and mouse chromosomes are telocentric, a tri-
ple staining of telomeres, centromeres (with human CREST anti-
serum), and ATRX was performed in mouse ES cells to validate
ATRX association at the telomeres (Fig. 2A). Finally, immunoflu-
orescence analysis using a different source of anti-ATRX antibody
gave the same staining pattern at the telomeres and pericentric
heterochromatin in ES cells (Fig. 1C; Supplemental Fig. S1C).
In somatic mouse and human cells, includingmouse NIH3T3
and L cells and human HT1080 and HeLa cells, ATRX mainly ac-
cumulated at the pericentric heterochromatin but not at the
telomeres (data not shown), suggesting that ATRX localization at
ES cell telomeres may potentially be linked to the pluripotent state
of the ES cells. To further investigate whether ATRX incorporation
at the telomere was associated with cellular pluripotency, we in-
cluded EG cells in our analysis. We observed distinct ATRX locali-
zation at the telomeres in two differentmouse EG cell lines, EGRA3
(Fig. 2B) and EGRA2 (Fig. 2C).
ATRX localizes at telomeres during S phase of the cell
cycle in ES cells
In our previous study, we have shown that MYC-H3.3 (H3.3 pro-
tein with a MYC epitope tag) is incorporated into the telomere
chromatin in ES cells during the time of telomere replication and
processing (Wong et al. 2009). For the preliminary determination
of the timing of ATRX localization at the telomeres, combined
5-bromo-29-deoxyuridine (BrdU) staining and immunofluores-
cence analysis was performed on ES129.1 cells (Supplemental Fig.
S3A–C). In BrdU-negative, non-S-phase cells, ATRX staining was
enhanced at the pericentric heterochromatin (indicated by stron-
ger DAPI staining) but not noticeably at the telomeres, as indi-
cated by the lack of punctate spots that typify telomeric staining.
However, in BrdU-positive cells, particularly during mid-to-late
S phase, punctate signals indicative of telomeric ATRX staining
Figure 1. Enrichment of ATRX at telomeres in mouse ES cell lines, ES129.1 and W9.5. Two sources of
antibodies against ATRX (H300 and D19) were used in immunofluorescence analysis. (A,B) In in-
terphase ES129.1 and ES-W9.5 cells, ATRX (Aiii,Biii, green; H300) was found at the telomeres (arrows)
and pericentric heterochromatin (for ATRX localization at pericentric heterochromatin, as indicated by
centromeric CREST staining, see Supplemental Fig. S1). Telomeric localization of ATRX (Aiii,Biii, green)
was confirmed by telomere FISH (Aii,Bii, red). (C ) Immunofluorescence analysis using a second source of
antibody also showed ATRX (ii, red; D19) enrichment at the telomeres (arrows) in interphase ES129.1
cells, as evident from its colocalization with TERF1 (iii, green).
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were significantly increased, suggestive of the binding of ATRX at
the telomeres during the period of DNA replication.
In order to clearly determine the timing of ATRX recruitment
at the telomeres, we performed immunofluorescence analysis on
synchronized ES129.1 cells (arrested at G1/S using a thymidine-
block protocol) (Fig. 3). Following the release of cells from G1/S
thymidine-induced block, cell-cycle progression was determined
by fluorescence-activated cell sorting (FACS) analysis (Supple-
mental Fig. S3D), which indicated that ES129.1 cells released from
G1/S-thymidine block progressed through S phase at 4–6 h post-
release, enteredM phase at 8 h, and re-entered G1 phase at 10 h. At
0 h, less than 20%of cells showed positive telomeric localization of
ATRX. After the initial 2 h post-G1/S release, ATRX level at telo-
meres became apparent (Fig. 3A; Supplemental Table S1). ATRX
recruitment predominantly occurred at mid-to-late S phase, with
74.29% and 82.86% of cells showing five or more positive ATRX
binding at the telomeres per cell after 4–6 h of release (Fig. 3B,C;
Supplemental Table S1), respectively, in synchrony with the time
of telomere replication and processing (Verdun and Karlseder
2006, 2007). Atmitosis (after 8 h of release), ATRXdissociated from
the telomeres but remained associated with the pericentric het-
erochromatin (Fig. 3D,E). Similar results were obtained when
combined cross-linked chromatin immunoprecipitation (ChIP),
and dot-blot assay was used to assess the association of ATRX,
MYC-H3.3, TERF1 (telomere binding factor), and histoneH4 at the
telomeres in these synchronized ES cell population (Supplemental
Fig. S4). As previously described (Wong et al. 2009), MYC-H3.3
level at the telomeres increased significantly during S phase and
remained prominent as cells entered mitosis. ChIP/dot blot anal-
ysis using antibodies against ATRX also showed a clear association
of ATRX at the telomeres during S phase, but ATRX level at the
telomeres reduced significantly during mitosis. Both TERF1 and
histone H4 levels at the telomeres remained high throughout the
entire cell cycle, in particular after the
entry of cells into S phase. The increases
in TERF1 and H4 levels could be attrib-
uted to an increase in the activity of
telomere replication as cells progressed
through S phase. ChIP using rabbit IgG
antibody did not result in any significant
enrichment of telomeric DNA. Together,
these results provided support that ATRX
association at the telomeres is coupled
with the timing of telomere replication
and chromatin assembly in S phase of the
cell cycle.
Cellular differentiation of ES cells leads
to decreased ATRX signals at the
telomeres
In order to examine if the localization of
ATRX at the telomeres was affected by
cellular differentiation, we induced dif-
ferentiation of ES129.1 cells by treatment
of leukemia inhibitory factor (LIF) with-
drawal and retinoid acid (RA) supplement
as previously described (Wong et al.
2009). Prior to differentiation, >90% of
these cells expressed the stem-cell surface
marker POU5F1 (also known as OCT4).
After 3 d of differentiation, less than 50%
expressed POU5F1. By 6 d, POU5F1was barely detectable (data not
shown).
We demonstrated the presence of MYC-H3.3 at telomeres in
undifferentiated interphase ES 129.1 cells as previously described
(Fig. 4A; Wong et al. 2009). MYC-H3.3 signals remained present at
the telomeres after 6 and 9 d of induction (data not shown).
However, after 12 d,MYC-H3.3 signals at the telomereswere barely
detectable (Fig. 4B). In addition, the induction of differentiation of
mouse ES cells also led to a significant increase inH4K20me3 levels
at the telomeres, as previously observed (Supplemental Fig. S5;
Wong et al. 2009).
Like MYC-H3.3, ATRX association at the telomeres was not
noticeably affected by the induction of cellular differentiation for
6 and 9 d (Fig 4C; although there was a slight decrease in ATRX
telomeric signals after 9 d of differentiation), but it was greatly re-
duced after 12 d of induction (Fig. 4D). The combined immuno-
fluorescence and quantitative assay confirmed that ATRX staining
at the telomeres remained prominent in ES129.1 cells after 6 and
9 d of induction of cellular differentiation (Supplemental Table S2).
Telomeric localization of ATRX in these cells was only significantly
reduced after 12 d of induction of differentiation, with only about
17.14% of cells showing five or more positive ATRX staining per
cell (Supplemental Table S2). It is important to note that the loss
of ATRX signals at the telomeres in differentiated ES129.1 cells
(12 d post induction of differentiation) was not contributed by
a decrease in the number of cells in S phase because these cells were
clearly undergoing DNA replication, as evident from the positive
BrdU staining (Supplemental Fig. S6).
ATRX colocalizes with H3.3 at the telomeres in ES cells
Both the reported endogenous full-length and truncated ATRX
(different proteins of 280 and 265 kDa) are highly conserved
Figure 2. Cellular distribution of ATRX in mouse ES cell lines ES129.1 and W9.5 and in mouse EG cell
lines EGRA2 and EGRA3. (A) In interphase ES129.1 cells, a triple-staining immunofluorescence analysis
showed clear colocalization of ATRX (iv, green) with telomere FISH signals (iii, red), without any CREST
signal (arrows). ATRX localization at pericentric heterochromatin was indicated by its close proximity to
the centromeric CREST staining (ii, blue; arrowheads). (B,C ) In interphase EGRA3 and EGRA2 cells, ATRX
(Biii,Ciii, green) was similarly enriched at the telomeres (arrows). Telomeric localization of ATRX (Biii,Ciii,
green) was confirmed by telomere FISH (Bii,Cii, red).
ATRX at the telomeres
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between mouse and human. Although the effects of deleting the
helicase domain of the full-length ATRX have been reported
(Garrick et al. 2006), little is known of the functions of the ADD
domain and the truncated ATRX. PHD fingers are a common fea-
ture of chromatin-related proteins and are highly specialized
methyl-lysine binding domains with a marked preference for
H3K4 (1ARTK4). H3.3 has the same protein sequence as H3 (except
for five amino acids at S31, A87, I89, G90, and S96), including its
K4 residue being a target site for histone methylation (Loyola et al.
2006).
Given the common association of PHD domain with lysine
residue on histone H3, we hypothesized that the localization of
ATRX at the telomeres was dependent on H3.3 loading at the
telomeres. The localization of ATRX and MYC-H3.3 at the telo-
meres in interphase ES129.1 cells lent further support for this
possibility. To investigate such a possibility, we performed immu-
nofluorescence analysis on ES129.1-MYC-H3.3 cells (Fig. 5). In
undifferentiated ES129.1 cells, ATRX was clearly colocalized with
MYC-H3.3 in ES129.1 cells (Fig. 5A). The colocalization between
ATRX and MYC-H3.3 remained prominent after 6 d (Fig. 5B) and
9 d (data not shown) of induction. After 12 d, the costaining of
ATRX and MYC-H3.3 was barely detectable (Fig. 5C). These results
suggest that ATRX recruitment at ES cell telomeres was likely to
be mediated via interaction with H3.3 up to 12 d of induction
of cellular differentiation.
As we previously described, H3.3S31P staining at the telo-
meres in ES cells diminished 3 to 6 d (instead of after 12 d) fol-
lowing the induction of differentiation (Wong et al. 2009). The
reason for the faster rate of H3.3S31P dissociation than of MYC-
H3.3 and ATRX (Figs. 4, 5) from the telomeres following the in-
duction of differentiation is unknown.
Nevertheless, our study shows that the
more rapid loss in the level of H3.3S31P at
the telomeres in metaphase cells (Wong
et al. 2009) was not due to an overt loss
of H3.3 association at the telomeres but
likely to be the consequence of a reduc-
tion in the phosphorylation of H3.3, the
regulatory mechanism of which remains
the subject of future studies.
ATRX directly interacts with H3.3
through its K4 residue
Based on the known association of PHD
domain with K4 residue on histone H3,
we further hypothesized that the inter-
action between ATRX and H3.3 at the
telomeres occurred through the direct as-
sociation of ATRX with the K4 residue of
H3.3. As a positive control, we showed
clear localization ofMYC-H3.3wtK4 (wild
type) with ATRX in ES cells (Fig. 6A). To
investigate how the loss of K4 in MYC-
H3.3 might affect ATRX and H3.3 interac-
tion, we generated a MYC-H3.3 construct
carrying a mutation in K4. The muta-
tionwas introduced using PCR-based site-
directed mutagenesis, followed by tran-
sient transfection into ES129.1 cells. The
overexpression of MYC-H3.3mutK4 did
not affect its localization to telomeres in
ES129.1 (Fig. 6B), but it resulted in a significant reduction in the
level of ATRX association with MYC-H3.3mutK4 at telomeres
compared to nontransfected ES129.1 cells (Fig. 6C), with the ex-
tent of this association being inversely proportional to the ex-
pression level of MYC-H3.3mutK4 (Fig. 6D; Supplemental Table
S3). As for the control cells, ATRX signal intensity remained
prominent and was not affected by the expression levels of MYC-
H3.3wtK4.
To further determine the interaction betweenATRXandH3.3,
we transiently transfected ES129.1 cells with either MYC-H3.3 or
MYC-H3.3mutK4 and performed immunoprecipitation and West-
ern blot analysis using anti-ATRX and anti-MYC antisera (since
anti-H3.3 antiserum is not available). As shown in Figure 6E, im-
munoprecipitation with anti-ATRX antiserum successfully ‘‘pulled
down’’ MYC-H3.3 in ES129.1 cells expressing MYC-H3.3 but did
not pull downMYC-H3.3mutK4 in ES129.1 cells expressing MYC-
H3.3mutK4, providing further evidence for the interaction be-
tween the two proteins.
ATRX RNAi-knockdown affects telomere integrity
in mouse ES cells
To study the normal functional role of ATRX at the telomeres in
ES cells, we used two sources of RNAi-oligonucleotides system
(Ambion and Invitrogen) to deplete ATRX (Fig. 7; Supplemental
Fig. S7B). Initial experiments by real-time reverse transcription
PCR assay confirmed the specificity and efficiency of three sets of
oligonucleotides for the knockdown in mouse ES129.1 cells, with
these siRNA oligonucleotide duplexes giving up to about 70%–
80% depletion of ATRX expression (data not shown). Importantly,
Figure 3. Timing of telomeric loading of ATRX. We previously showed that MYC-H3.3 was loaded at
the telomeres in interphase ES129.1 cells during S phase (Wong et al. 2009). Here, ES129.1 cells were
similarly synchronized using a thymidine-induced G1/S-block protocol (for FACS analysis, see Supple-
mental Fig. S3). (A–C ) ATRX (iii, green)was present at the telomeres in cells from2–6 h post-release from
G1/S block, as indicated by colocalization with telomere FISH signals (ii, red). (D) By mitosis (8 h post-
release), ATRX (iii, green) completely delocalized from the telomeres (ii, red; indicated by telomere FISH
signals) but remained at pericentric heterochromatin (arrowheads). (E ) Enlarged images of the boxed
areas shown in D, showing no ATRX signals at the telomeres (arrows) but strong localization of ATRX (iii,
green) at the pericentric regions (arrowheads); note that the telocentric nature of the mouse chro-
mosomes meant an inevitable display of the observed colocalization of telomeric FISH signals with the
centromeres at this resolution. At 10 h post-release, the cells re-entered G1 phase of the cell cycle (data
not shown).
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these siRNAduplexes also resulted in a robust reduction in ATRX at
the protein level as shown in Western blot analysis (Fig. 7; Sup-
plemental Fig. S7A). ATRX RNAi-depletion had no immediate ef-
fect on cell-growth during the initial 24 h, although it led to
a slight reduction in cell-growth 48 h post RNAi-knockdown (data
not shown; and in agreementwith a similar observation previously
reported [Garrick et al. 2006]). Changes in telomere length in
mouse ES cells subjected to ATRX RNAi-knockdown for 48 h were
determined using Southern blot analysis; however, no significant
change was observed (Supplemental Fig. S7C).
We have previously shown that RNAi-depletion of H3.3 in
mouse ES cells induced telomere-dysfunction phenotypes (Wong
et al. 2009), as indicated by an increase in the number of cells with
telomere induced dysfunctional foci (TIF; a marker for DNA dam-
age at the telomeres identified by gamma-H2AFX [formerly known
as gamma-H2AX] staining) (Hockemeyer et al. 2005). To assess the
effects of ATRX-depletion on telomere structural integrity, we
quantitated the level of TIFs in cells subjected to RNAi-depletion of
ATRX (Fig. 7C–E, Supplemental Fig. S7B; Supplemental Table S4).
In ES129.1 cells transfected with control RNAi oligonucleotides,
only about 5.88%–9.41% of cells showed five or more TIFs per
cell. Importantly, ATRX-specific RNAi-knockdown caused three- to
fivefold (9.41% increased to 29.80%–34.90%, and 5.88% increased
to 29.41%, depending on the source of RNAi-oligonucleotides
system) increase in the population of cells showing five or more
TIFs per cell (Supplemental Table S4). Although TIFs were mainly
seen at telomeres in interphase cells, they were occasionally seen at
the telomeres in metaphase cells (Fig. 7E). In contrast, ATRX RNAi-
knockdown in mouse NIH3T3 cells did not lead to a significant in-
crease in the number of cells containing five or more TIFs (data not
shown). These results indicated a direct and specific contribution of
ATRX to the functional integrity of telomere chromatin in ES cells.
ATRX RNAi-knockdown affects
CBX5 binding at the telomeres
in mouse ES cells
HP1 was first discovered in Drosophila
melanogaster as a non-histone chromo-
somal protein associated with heterochro-
matin (James and Elgin 1986). It is phylo-
genetically conserved in many eukary-
otes. ThreemammalianHP1proteins have
been identified: HP1 alpha (CBX5), HP1
beta (CBX1), and HP1 gamma (CBX3). A
variety of functions have been described
for HP1, including heterochromatin or-
ganization, transcription regulation, DNA
replication and repair, and chromatin
remodeling (Maison and Almouzni 2004;
Fanti and Pimpinelli 2008). In Drosoph-
ila, HP1 is a protein essential for telomere
stability; mutations in HP1 cause severe
telomere fusions and chromosome break-
age. Although there is evidence in mam-
malian cells for HP1 involvement in telo-
meremetabolism (Minc et al. 1999; Sharma
et al. 2003), the function of HP1 in telo-
mere homeostasis is less well defined.
Interestingly, our immunofluores-
cence analysis showed prominent CBX5
colocalization with ATRX at the telo-
meres, in addition to enrichment at per-
icentric heterochromatin, in undifferentiated mouse ES cells (Fig.
8A). The signal intensity of CBX5 telomeric association in mouse
ES cells was much higher compared with those in somatic human
and mouse cells (for example, see Fig. 8D). Furthermore, as was
seen for ATRX and MYC-H3.3, the induction of differentiation in
ES cells by LIFwithdrawal and RA treatment led to a decrease in the
Figure 4. Cellular localization of MYC-H3.3 and ATRX in differentiated ES cells. (A,B) MYC-H3.3
construct was transfected into ES129.1 cells and induced with 1mMdoxycycline for 24 hMYC-H3.3 (Aii,
red) colocalized with TERF1 (Aiii, green) at the telomeres (examples shown by the arrows) in un-
differentiated (0 day) interphase ES 129.1 cells. MYC-H3.3 and ATRX signals remained apparent at the
telomeres after 6 and 9 d of induction (data not shown). However, no enrichment ofMYC-H3.3 (Bii, red)
was detected at the telomeres (indicated by TERF1 staining; Biii, green) 12 d following the induction of
differentiation. (C,D) Likewise, ATRX association at the telomeres was also not noticeably affected by the
induction of differentiation for 6 and 9 d (Ciii, green), but ATRX (Diii, green) completely delocalized from
the telomeres after 12 d of induction of cellular differentiation.
Figure 5. Colocalization of ATRX and MYC-H3.3. (A) ATRX (iii, green)
clearly colocalized with MYC-H3.3 (ii, red) in undifferentiated (0 day)
interphase ES129.1 cells. (B) The colocalization of ATRX (iii, green)
with MYC-H3.3 (ii, red) remained prominent after 6 d of differentia-
tion. (C ) However, after 12 d of differentiation, the colocalization of
ATRX (iii, green) with MYC-H3.3 (ii, red) was greatly reduced. Occa-
sionally, strong ATRX signals were detected in the 6- and 12-d cells, but
these signals were not colocalized with the telomeres (Biii,Ciii, green;
arrowheads).
ATRX at the telomeres
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association of CBX5 with the telomeres (Fig. 8B,C), whereas CBX5
signal at the pericentric heterochromatin remained prominently
high. Given the strong association of ATRX with CBX5, immu-
nofluorescence analysis was performed in ES129.1 cells to examine
the effect of ATRX-depletion on CBX5 recruitment at the telo-
meres. As shown in Figure 9, RNAi-mediated knockdown of ATRX
caused an extreme reduction in the binding of CBX5 at the telo-
meres in ES cells, suggesting a direct function of ATRX as chro-
matin remodeler in recruiting CBX5 to the telomere chromatin in
ES cells. It is also interesting to note that CBX5 signals remained
high at the pericentric heterochromatin following ATRX-depletion.
This is not surprising, given that CBX5 could be recruited by an
alternative mechanism such as via binding to the H3K9me3 on
pericentric heterochromatin.
Discussion
The localization of ATRX to the pericentric heterochromatin
(recruited by CBX5 and MECP2) (Kourmouli et al. 2005; Nan et al.
2007) and the PML nuclear bodies (recruited by DAXX) (Xue et al.
2003; Ishov et al. 2004) has been well documented. Here, we have
demonstrated the localization of ATRX at the interphase telomeres
in two different pluripotent cell types (ES and EG cells), in addition
to its binding at the pericentric heterochromatin as previously
reported (Kourmouli et al. 2005; Nan et al. 2007) for nonplurip-
otent cell types such as NIH3T3, L cells, and HT1080 cells. This
observation, in conjunction with our previous report of a distinct
enrichment of H3.3 in the ES cells (Wong et al. 2009), suggests the
presence of a unique chromatin at the telomere that is modulated
Figure 6. The effects of H3.3 lysine-4 mutation on its interaction with ATRX by immunofluorescence and immunoprecipitation/Western blot
analysis. (A) As a positive control, we showed a clear colocalization of MYC-H3.3 (ii, red) with ATRX (iii, green) in ES129.1 cells. (B,C ) Themutation of K4
(lysine to alanine) residue was introduced by site-directed PCRmutagenesis. TheMYC-H3.3mutK4 plasmid DNAwas transiently transfected intomouse
ES129.1 cells. The expression of MYC-H3.3mutK4 (Biii, green; indicated by arrows) in ES129.1 cells (cell on the right) did not affect its telomeric
localization (as indicated by telomere FISH signals; Bii, red) but resulted in a significant reduction in the association of ATRX (Ciii, green) with MYC-H3.3
(Cii, red; indicated by arrows) at telomeres compared with cells not expressing MYC-H3.3mutK4 (cell on the left). (D) In ES129.1 cells expressing either
MYC-H3.3wtK4 or MYC-H3.3mutK4, the signal intensities of MYC-H3.3wtK4/ATRX and MYC-H3.3mutK4/ATRX were quantitated. For each cell, the
intensities for five sets of colocalizing MYC-H3.3wtK4/ATRX and MYC-H3.3mutK4/ATRX signals were measured, and the average intensities were
determined. In total, 25 cells were assessed (Supplemental Table S3). As shown in the scattered plot, in ES cells expressingMYC-H3.3wtK4, ATRX signal
intensity remained high regardless of MYC-H3.3wtK4 signal intensity, whereas, an inverse relationship between the expression level of MYC-
H3.3mutK4 and ATRX signal intensity was observed, suggesting that MYC-H3.3mutK4 expression affects ATRX association. (E ) Immunoprecipitation
with anti-ATRX antiserum pulled down MYC-H3.3 in ES129.1 cells expressing MYC-H3.3 (lane 2) but failed to pull down MYC-H3.3mutK4 in ES129.1
cells expressing MYC-H3.3mutK4 (lane 5). As a positive control, immunoprecipitation with anti-MYC antiserum also pulled down MYC-H3.3 (lane
3) and MYC-H3.3mutK4 (lane 6). The two bands above MYC-H3.3 in lanes 3 and 6 are heavy and light chains of the anti-MYC antiserum (clear
arrowheads).
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in a significant way by ATRX and H3.3. Interestingly, the prom-
inent presence of ATRX at the telomeres up to 12 d of induction of
differentiation in these cells indicates that ATRX does not disso-
ciate from the telomeres immediately after the loss of cellular
pluripotency andmay continue to play an as yet undefined role in
the early stages of the undifferentiated cellular state.
Wehave shown that ATRXbinding at the telomeres in ES cells
occurs during late S/G2 phase and is coupled with the events of
H3.3 loading and telomere replication timing at S phase of the cell
cycle. By immunofluorescence and immunoprecipitation analysis
in ES cells, we have further demonstrated a direct interaction be-
tween ATRX andH3.3. The reduction in the colocalization of these
two proteins at the telomeres following the mutation of the K4
residue onH3.3 clearly indicates that H3.3 acts as a docking site for
ATRX recruitment. Our observation of a direct interaction between
ATRX and H3.3 is the first to be reported in mammalian cells.
Although ATRX depletion did not induce an extremely severe
telomere dysfunction phenotype such as telomere fusions, we
observed a robust increase in DNA damage/TIF phenotype fol-
lowing ATRX depletion, indicating a novel role of ATRX for the
proper maintenance of telomere chromatin integrity in ES cells.
A similar DNA damage/TIF phenotype was previously observed
in H3.3 knockdown in these cells (Wong et al. 2009). The lack of
amore severe telomere dysfunction phenotype could be due to the
relatively short knockdown-time permissible in these experiments.
Another possibility is that compromise in the telomere chromatin
integrity following ATRX depletion may take many cell divisions
to take effect. Consistent with this, an earlier study demonstrated
that ES cells lacking ATRX, despite having a slower rate of cell di-
vision, did not exhibit any serious change inmitotic index (Garrick
et al. 2006). This indicates that loss of ATRX does not immediately
cause a severe cell cycle defect and is consistentwith the absence of
an observable severe telomere dysfunction phenotype and cell-
growth defect in our ATRX-depleted ES cells.
The role of ATRX as a chromatinmodifier is well documented.
It is possible that ATRX, through interactionwithH3.3 (Wong et al.
2009), acts to maintain a unique telomere chromatin state. Spe-
cifically, we propose that such an interaction, coupled to the
telomere replication machinery (Verdun and Karlseder 2006,
2007), provides a primary epigenetic determinant that directly
controls the assembly of a functionally essential and protected
telomere structure in ES cells. Our observation of the direct function
Figure 7. Effect of ATRX RNAi-knockdown on telomere integrity in mouse ES cells. (A) Western blot analysis of ES129.1 cells transfected with ATRX-
specific RNAi oligonucleotide sets (set 3 and sets 1–3 from Invitrogen) using anti-ATRX and anti-beta-tubulin antisera. (i ) Data are presented in histograms
by normalization of the intensity of ATRX levels against the intensity of beta-tubulin levels. (ii ) ATRX RNAi-depleted cells showed a significant reduction of
;90% in ATRX protein level (arrows; lanes 3,4) 48 h after the transfection, compared with nontransfected cells (lane 1) and cells transfected with
scrambled control RNAi oligonucleotides (lane 2). The equal loading of protein was achieved by normalization against the beta-tubulin level. (B) Induction
of TIFs by ATRX-inhibition using ATRX RNAi oligonucleotide (set 3 and sets 1–3 from Invitrogen and set 2 from Ambion, respectively) for 48 h. Data are
presented in histograms by subgrouping the cells according to the number of TIFs per cell (less than five 5 TIFs, five to nine TIFs, 10 to 14 TIFs, and more
than 14 TIFs). A normal cell can contain one to two TIFs on average; thus, a threshold of four or more TIFs was used, as described in other studies
(Hockemeyer et al. 2005). When transfected with ATRX-RNAi oligonucleotides, the number of cells with five or more TIFs (85 cells were counted for each
experiment) by three- to fourfold (increased from 9.41% to as high as 29.8%–34.90%, with an average increase of 20.39%–25.49%). In this study, we
only counted the number of TIFs in interphase ES129.1 cells although in some metaphase cells, TIFs were also present at the telomeres following RNAi-
depletion of ATRX. We also performed RNAi-knockdown using ATRX-specific RNAi oligonucleotide sets purchased from Ambion, showing a significant
reduction of;80% in ATRX protein level and a fivefold increase in the number of cells with five or more TIFs 48 h after the transfection (see Fig. S7). (C–E )
Immunofluorescence analysis of ES129.1 cells subjected to 48-h knockdown with either control (C ) or ATRX-specific (D,E ) RNAi-duplex oligonuclotides
using anti-gamma-H2AFX (Cii,Eii; green) antiserum. Increased number of TIFs was detected at telomeres (indicated by telomere FISH analysis; Diii,Eiii) in
cells depleted of endogenous ATRX (arrowheads show some examples of TIFs).
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of ATRX in recruiting CBX5 to the telomeres further supports its
role in the maintenance of telomere chromatin integrity in ES
cells. Although it may seem conflicting that H3.3, being a marker
for active chromatin, takes part in the recruitment of ATRX and
CBX5 (given their common association with repressive chroma-
tin), these proteins may act to strike a balance in telomere chro-
matin state to allow continual telomere-renewal but yet maintain
an essential compacted structure. The phenomenon of having
such a dynamic ‘‘open and closed chromatin state’’ is not new.
Indeed, it has been well documented that a dynamic balance be-
tween open chromatin and closed heterochromatin is essential for
vertebrate centromere activity (Wong et al. 2007; Nakano et al.
2008; Chueh et al. 2009). Future studies looking at the detailed
mechanisms of action between these chromatin regulators and
their interaction with histone methyltransferases SUV39H1/2
and SUV420H1/2 and with DNA methyltransferases DNMT3A/B
and DNMT1 should elucidate novel pathways on the regulation of
telomeric chromatin and telomere length homeostasis.
Although HP1 is known to play a direct role in regulating
telomere length, capping, and transcription activity of retroele-
ments in Drosophila (Fanti et al. 1998), less is known of its direct
function at mammalian telomeres. Interestingly, a recent study
described the association of HP1 proteins (CBX1, CBX3, and
CBX5) with ALT (alternative lengthening of telomeres)-associated
PML nuclear bodies and its role in compacting telomeric DNA in
human ALT cancer cells (Jiang et al. 2007, 2009). It remains to be
investigated if ALT cancer cells or other tumors have adopted
a similar mechanism as ES cells in the regulation of telomere
chromatin. Furthermore, it will be interesting to examine if H3.3,
ATRX, and CBX5 also play a role in the establishment of telomeric
chromatin during the differentiation and reprogramming of early
mouse embryos, given that an alternative ALT-like recombination-
based mechanism involving telomere sister-chromatid exchange
has been proposed to be the driving force for the resetting of
telomere length at early cleavage embryos (Liu et al. 2007).
Methods
Cell cultures
Cell lines including humanHT1080 (fibrosarcoma), HeLa (cervical
cancer cells), mouse NIH3T3, and L cells (transformed fibroblasts)
were cultured in DMEM with 10% FCS. Mouse ES129.1 and ES-
W9.5 in DMEMwith 15% heat-inactivated FCS and 13 103 units/
mL of leukemic inhibiting factor (LIF) and 0.1 mM b-mercaptoe-
thanol. EG cell lines EGRA2 and EGRA3 were derived from pri-
mordial germ cells of strain 129 mice (J McWhir, The Roslin In-
stitute, Scotland). They were cultured on LIF-expressing STO
fibroblast feeder cells.
Antibodies
Primary antibodies used were as follows: rabbit polyclonal antisera
against TERF1 (Iwano et al. 2004) and ATRX (H300 and D19; Santa
Cruz Biotechnology); mouse monoclonal antiserum against MYC
tag (Invitrogen), OCT4 (also known as POU5F1; Santa Cruz Bio-
technology); gamma-H2AFX phosphorylated at Ser 139 (Upstate
Biotechnology), CBX5 (Chemicon), and BrdU (Roche; conjugated
with FITC); and human autoimmune anti-centromere antiserum
CREST6 (predominantly anti-CENPA and -CENPB). Secondary
antisera were donkey anti-human Texas Red (Jackson Laboratory),
and donkey anti-mouse or anti-rabbit Alexa Fluoro 488/594/647
(Molecular Probes, Invitrogen).
Immunofluorescence analysis, FISH, and BrdU incorporation
Cells were treated with microtubule-depolymerizing agent Colce-
mid for 1 h at 37°C, harvested for hypotonic treatment in 0.075M
Figure 8. Colocalization of CBX5 with ATRX at the telomeres in ES cells.
(A) A triple staining/immunofluorescence analysis showing colocalization
of CBX5 (iv, blue) with ATRX (ii, green) at the pericentric heterochromatin
(arrowheads) and telomeres (iii, red; indicated by telomere FISH). (B,C )
CBX5 (Biii, red) colocalized with TERF1 (Bii, green) at the telomeres (ex-
amples shown by the arrows) in undifferentiated (0 day) interphase ES
129.1 cells. CBX5 signal remained apparent at the telomeres after 6 and
9 d of induction (data not shown). However, CBX5 localization (Ciii, red)
at the telomeres (Cii, green) was greatly decreased 12 d following the
induction of differentiation. (D) In somatic cells, e.g., NIH3T3, CBX5 (iii,
red) localized mainly at pericentric heterochromation, but its association
with the telomeres (arrowheads; ii, green) was below detection.
Figure 9. Effect of ATRX RNAi-knockdown on telomeric association of
CBX5 in mouse ES cells. (A–C ) ES129.1 cells transfected with scramble
RNAi oligonucleotide (A) and ATRX-specific RNAi oligonucleotide sets
(B–C; set 3 and sets 1–3 [Invitrogen]) for a period of 48 h. Transfection of
ES129.1 cells with scrambled RNAi oligonucleotide did not affect locali-
zation of CBX5 (Aiii, red) at the telomeres (arrows), as indicated by co-
staining with TERF1 (Aii, green). However, RNAi depletion of ATRX with
RNAi oligonucleotide sets, set 3 (B) and sets 1–3 (C ) led to a significant
dissociation of CBX5 from the telomeres (arrowheads) in ES129.1 cells.
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KCl, cytospun on slides, and incubated in KCM buffer (120 mM
KCl, 20 mMNaCl, 10 mM Tris.HCl at pH 7.2, 0.5 mM EDTA, 0.1%
[v/v] Triton X-100, and protease inhibitor) (Uren et al. 2000;Wong
et al. 2005, 2007). Slides were blocked in KCM buffer contain-
ing 1% BSA and incubated with the relevant primary and sec-
ondary antibodies for 1 h at 37°C. After each round of anti-
body incubation, slides were washed three times in KCM buffer.
Slides were then fixed in KCM with 4% formaldehyde and
mounted in mounting medium (Vetashield). Images were col-
lected using a fluorescence microscope linked to a CCD camera
system.
For telomere-FISH, slides were fixed in cold methanol fol-
lowed by dehydration in an ethanol series prior to denaturation
and hybridization with Cy3-conjugated telomere DNA probe
(Dako). For BrdU staining, cells were incubated with 10 mM BrdU
(Sigma) for 1 h. BrdU incorporationwas assessed by a denaturation
protocol using 0.5 N hydrochloric acid, followed by immunoflu-
orescence analysis with anti-BrdU FITC antibody (Roche).
Cell-cycle synchronization and FACS analysis
Cells were treatedwith 2mMthymidine for 12h, released from cell
cycle blockage by washing with warm medium, and incubated in
medium at 37°C for various time points. For FACS analysis, cells
were harvested, washed in 13 PBS, fixed with ice-cold ethanol,
stained with propidium iodide, and analyzed on a LSR II Becton
Dickinson Flow Cytometry Analyzer.
Generation and transfection of MYC-tagged H3.3
and MYC-tagged H3.3mutK4 constructs
The generation of pcDNA4/TO/MYC-H3.3 (tetracycline-inducible
expression vector expressing MYC-H3.3) has been described
(Wong et al. 2009). The mutation on K4 residue was performed
by PCR/site-directed mutagenesis. Using pcDNA4/TO/MYC-H3.3
as DNA template, the 59 and 39 fragments of pcDNA4/TO/MYC-
H3.3K4 carrying amutation in K4 residuewere generated using the
following primers: H3.3K4Aforward, 59-GCTCGTACAGCGCAGA
CTGCC-39 (carrying a mutated site AAG to GCG, underlined);
H3.3K4Areverse, 59-GGCAGTCTGCGCTGTACGAGC-39 (carrying
a mutated site CGT to CGC, underlined); MYCforward, 59-CGCA
AATGGGCGGTAGGCGTG-39; H3.3MYCreverse, 59-GAAGGGCCC
TTAAGCACGTTCTCCACGTAT-39 (carrying an ApaI site, under-
lined).
The two fragments generated were purified, annealed, and
subjected to PCR extension. Subsequently, overlapping PCR
amplification was performed using MYCforward primer and
H3.3cMYCreverse primer corresponding to 59 and 39 fragments of
MYC-H3.3, respectively. The resulting MYC-H3.3mutK4 fragment
was digested with BamHI and ApaI and cloned into pcDNA4/TO/
MYC-HisTA at BamHI and ApaI.
RNAi-depletion of ATRX and real-time PCR
Transfections of ATRX–RNAi-duplex oligonucleotides were per-
formed using Lipofectamine 2000 (Invitrogen). The RNAi-duplex
oligonucleotides (three sets of oligonucleotides) corresponding to
the ATRX gene were purchased from Invitrogen and Ambion.
These oligonucleotides have been prevalidated to confirm their
targeting specificity. A set of control scrambled RNAi-duplex oli-
gonucleotides was also used. Cells were harvested 24–48 h post-
RNAi-knockdown for the assessment of the levels of ATRX by real-
time PCR analysis using the SYBR system (Applied Biosystems).
Four different sets of primers against ATRX cDNA were used for
real-time PCR analysis, and average ATRX expression levels post-
RNAi-knockdownwere calculated for each experiment. As internal
controls, specific primers corresponding to the housekeeping gene
actin were used in real-time PCR analysis. Changes in expression
levels were calculated according to the manufacturer’s instruction.
The ATRX and actin primer sets used for real-time PCR analysis
were as follows:
ATRX exon 1–2: 59 primer, 59-GTCCGAGCCAAAAACATGAC-39;
39 primer, 59-GTCATGAAGCTTCTGCACCA-39
ATRXexon18–19: 59primer, 59-GAGAAGTGGCAGGAGGGATT-39;
39 primer, 59-TGAGGACGTTTCACAGTTGC-39
ATRXexon27–28: 59primer, 59-AGCCAGTCGCTCATATCTCTG-39;
59 primer, 59-TCGGATCCACTTTCCTTCAC-39
ATRXexon 34–35: 59 primer, 59-CGTGAAACGAAGAGAAGCAA-39;
39 primer, 59-TGCTGGAGCCGTCTATTCAT-39
Actin: 59 primer, 59-TCCCTGGAGAAGAGCTACGA-39; 39 primer,
59-AGCACTGTGTTGGCGTACAG-39.
Western blot analysis and protein immunoprecipitation
Cells were washed with ice cold 13 PBS lysed with ice-cold 13
modified RIPA buffer (150 mM NaCl, 50 mM Tris-HCl at pH 7.5,
0.25% sodiumdeoxycholate, 0.1%NP40, 1mMNaF, 1mMsodium
orthovanadate, and protease inhibitor), followed by a 10-sec pulse
sonication. The lysate was collected after a 10-min centrifugation
at 12,000 rpm and boiled in SDS/PAGE sample buffer prior to
protein gel electrophoresis and Western blot analysis.
For immunoprecipitation, cells were lysed in ice-cold TBS
buffer (10 mM Tris at pH 7.5, 3 mM CaCl2, 2 mM MgCl2, and
protease inhibitor) containing 0.5% Tween 40 for 1 h and ho-
mogenized using a Dounce Homogeniser ‘‘Tight/A’’ pestle. Nuclei
were pelleted and incubated in digestion buffer (50 mM Tris at
pH 7.5, 320 mM sucrose, 1 mM CaCl2, 4 mMMgCl2, and protease
inhibitor) with MNase (4–16 units/mg DNA) at 37°C for various
time-courses. Reaction was stopped with the addition of 1/100 of
0.5 M EDTA. The nuclei were pelleted, and the supernatant was
collected. The pelleted nuclei were then lysed further in 13 lysis
buffer (1 mM Tris at pH 7.5, 0.1 mM EDTA, and protease inhibitor)
and centrifugated, and the supernatant was collected. The lysates
were then pooled and mixed (1:1 ratio) with incubation buffer
(50 mM NaCl, 20 mM Tris at pH 7.2, 5 mM EDTA, and protease
inhibitor).
Cell lysates were subjected to immunoprecipitation with 1–5
mg of antibodies overnight at 4°C with constant agitation. Fifty
microliters of 50% protein G–Dynabead (Invitrogen) was added to
the mixture for capturing the protein/antibody complexes. The
immunoprecipitated complexes were washed with wash buffer
three times (first wash with 50 mM Tris at pH 7.2, 10 mM EDTA,
and 50 mMNaCl; second wash with 50 mM Tris at pH 7.2, 10 mM
EDTA, and 100 mM NaCl; third wash with 50 mM Tris at pH 7.2,
10 mM EDTA, and 150 mM NaCl). The proteins were eluted by
the addition of 80 mL of 23 SDS-PAGE sample buffer followed by
boiling for 5 min. The beads were pelleted by centrifugation in
a microfuge, and the supernatant containing proteins were sub-
jected to SDS-PAGE analysis.
Pulse field gel electrophoresis and Southern blot analysis
Total genomicDNAwas digestedwith RsaI andHinfI and subjected
to either standard or pulse-field (6 V/cm for 20 h at 14°C; switch
times ramped linearly from 0.5 to 6 sec using CHEF PFGE Bio-
radsystem) gel electrophoresis, followed by Southern blot analysis
with a [g-32P]ATP-end-labeled (TTAGGG)4 telomere repeat probe.
Signal intensities were analyzed with Typhoon PhosphoImager-
System and ImageQuant software.
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Dot blot analysis
DNA (50 ng) was diluted with 0.6 M NaCl, denatured (by heating
DNA for 5 min at 100°C and cooling on ice for 5 min), transferred
onto Hybond N+ nitrocellulose membrane, and rinsed in 0.5 M
NH2SO4. The membrane was incubated in 0.4 N NaOH at room
temperature for 5 min, followed by neutralization with 23 SSC
twice. Subsequently, the membrane was subjected to Southern
blot analysis with a [g-32P]ATP-end-labeled (TTAGGG)4 telomere
probe. Signal intensities were analyzed with Typhoon Phos-
phoImager System and ImageQuant software.
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